| 2026-06-09 16:35 |
8-K |
["5.03", "5.07", "9.01"] |
other |
0.45
|
Authorized share increase from 300M to 450M approved at annual meeting; modest M&A signal but common for corporate flexibility. |
SEC · detail |
| 2026-05-21 17:07 |
8-K |
["1.01", "9.01"] |
other |
0.05
|
Public offering of common stock; no M&A signals present. |
SEC · detail |
| 2026-05-19 08:45 |
8-K |
["7.01", "8.01"] |
other |
0.05
|
Clinical trial data announcement for zovegalisib; no M&A signals present. |
SEC · detail |
| 2026-05-05 16:10 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine quarterly earnings announcement with no M&A-related content or implications. |
SEC · detail |
| 2026-04-27 09:15 |
8-K |
["7.01", "8.01"] |
other |
0.05
|
Clinical trial data announcement for zovegalisib triplet combination; no M&A signals. |
SEC · detail |